Peptide Half-Life Explained: Why Dosing Frequency Matters (2026)

Peptide half-life is the time it takes for plasma concentration of a peptide to drop to half its peak after dosing. It determines everything about your protocol: how often you inject, whether you can dose once weekly or need multiple daily doses, and how the peptide produces its effect (sharp pulse vs sustained elevation). A peptide with a 30-minute half-life dosed weekly produces no clinical effect; the same peptide dosed correctly (daily) works fine. This guide explains peptide half-life, why it matters, and gives you the actual half-life values for every commonly used research peptide so you can match your dosing to the molecule.

The reason half-life matters: peptides with short half-lives that are dosed too infrequently produce zero benefit. Peptides with long half-lives that are dosed too often produce side effects without proportional benefit. Matching dosing frequency to half-life is the single most important parameter in protocol design.

What Is Peptide Half-Life?

Half-life is a pharmacokinetic property: how long it takes for plasma concentration to fall to 50% of peak after dosing.

The math: after one half-life, 50% of the dose remains. After two half-lives, 25%. After three, 12.5%. After five half-lives, essentially zero (3%). Most peptides are clinically inactive after 4 to 5 half-lives.

For a peptide with 30-minute half-life: peak at injection, 50% at 30 min, 25% at 1 hour, 12% at 1.5 hours, essentially gone by 2 to 3 hours.

For a peptide with 7-day half-life: peak at injection, 50% at day 7, 25% at day 14, gone by day 35.

Half-Life Affects Dosing Frequency

The general rule: dose at intervals of 1 to 2 half-lives to maintain therapeutic levels.

The exception: peptides whose effect depends on a sharp pulse rather than sustained elevation (most GH-releasing peptides) need to be dosed once daily even if their half-life is short, because the pulse magnitude is what matters and re-pulsing too often blunts pituitary response.

Common Peptide Half-Lives

Growth hormone releasing peptides

Healing peptides

GLP-1 class

Direct anabolic and other

Why Some Peptides Have Surprising Dosing

Why Tesamorelin is daily despite 30-minute half-life

Tesamorelin’s GH-releasing effect produces downstream changes (IGF-1 elevation, fat mobilization) that persist much longer than the peptide itself. The 30-minute half-life of the peptide does not equal the duration of effect; the cascade it triggers lasts hours.

Why TB-500 is twice-weekly despite 2-3 day half-life

TB-500’s tissue effects accumulate; you do not need plasma elevation to maintain the wound-healing effect. Twice-weekly dosing maintains adequate exposure for the systemic effect.

Why DSIP is dosed daily despite 7-minute half-life

DSIP works by triggering downstream sleep architecture changes. The peptide itself clears fast but the effect on that night’s sleep persists. Daily dosing produces the cumulative effect needed for measurable benefit.

Half-Life and Cycle Length

Peptides with short half-lives (under 1 hour) tend to cause faster receptor desensitization because of the rapid pulses. Cycles of 6 to 12 weeks are typical.

Peptides with long half-lives (3+ days) produce sustained receptor activation, which can also desensitize but more slowly. Longer cycles (12 to 24 weeks) are often appropriate.

See our cycling guide for cycle length by peptide class.

Common Half-Life-Related Mistakes

• Once-weekly dosing of short-half-life peptides: dosing CJC-1295 (no DAC) once weekly produces almost no effect because the peptide clears in hours.
• Daily dosing of long-half-life peptides: dosing semaglutide daily would multiply weekly steady-state levels far beyond therapeutic range, causing severe side effects.
• Skipping doses on short-half-life protocols: missing 2 days of BPC-157 means 2 days of no peptide signaling. Consistency matters more for short half-life.
• Stacking incompatible half-lives: combining a 7-day-half-life peptide with a 30-minute one and dosing both weekly means the short one is essentially absent.
• Dosing GH peptides too frequently: even with short half-life, dosing CJC + Ipamorelin 3 times daily desensitizes receptors faster than once-daily dosing produces equivalent benefit.

Frequently Asked Questions

How is peptide half-life measured?

By taking blood samples at intervals after dosing and measuring plasma peptide concentration. The time to reach 50% of peak is the half-life. Most peptide half-lives are determined in clinical pharmacokinetic studies.

Does half-life vary between users?

Yes, modestly. Body weight, kidney and liver function, and individual metabolism affect half-life by 10 to 30%. The published half-life values are population averages.

What about depot or extended-release peptides?

Some peptides come in depot formulations (slow-release implants, microsphere injections) that artificially extend effect by slowing release. CJC-1295 with DAC is a chemical depot strategy; long-acting GLP-1 formulations like semaglutide depot use similar engineering.

How does half-life affect drug testing detection?

Detection windows are typically 4 to 6 half-lives. Short-half-life peptides clear within hours; long-half-life ones (semaglutide, CJC with DAC) are detectable for weeks. WADA testing focuses on metabolite detection which can extend the window further.

Where can I get peptides with the right dosing protocols?

For research-grade peptides shipped with peptide-specific dosing guidance in Indonesia and Southeast Asia, see our pricelist. We help first-time users set up protocols matched to each peptide’s half-life. Order directly via WhatsApp.

This article is for informational and research-use purposes only. Always consult a qualified medical professional before starting any new protocol.